News headlines about Steris (NYSE:STE) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Steris earned a news impact score of 0.17 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 45.7250410047796 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
- Technical Secrets – Steris Plc (NYSE: STE) – Alpha Beta Stock (alphabetastock.com)
- Steris Plc (STE) receives consensus rating of 2.00 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Middle East and Africa Patient positioning systems Market | Industry Analysis Forecast Report (emailwire.com)
- Global Endoscopic Mucosal Resection Market to Reach US$ 2,500 Mn by 2025 – Persistence Market Research (prnewswire.com)
- BRIEF-STERIS Plc Sees U.S. Tax Cuts And Jobs Act To Result In Tax Gain Of About $25 Mln In Q3 Fiscal 2018 (reuters.com)
STE has been the subject of several analyst reports. KeyCorp reaffirmed an “overweight” rating and set a $101.00 target price (up from $91.00) on shares of Steris in a research report on Thursday, November 2nd. Zacks Investment Research lowered Steris from a “buy” rating to a “sell” rating in a research report on Monday, November 6th. TD Securities raised their target price on Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Finally, Raymond James Financial raised their target price on Steris from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, October 16th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $79.50.
Steris (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.95 by ($0.01). Steris had a return on equity of 11.49% and a net margin of 5.59%. The business had revenue of $634.20 million during the quarter, compared to the consensus estimate of $629.02 million. During the same period last year, the business posted $0.89 earnings per share. The business’s revenue was down 1.9% on a year-over-year basis. equities analysts forecast that Steris will post 4.06 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd were given a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.35%. The ex-dividend date of this dividend was Tuesday, November 21st. Steris’s dividend payout ratio (DPR) is presently 73.81%.
In other news, insider Michael J. Tokich sold 11,000 shares of Steris stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $92.00, for a total value of $1,012,000.00. Following the completion of the transaction, the insider now directly owns 58,588 shares of the company’s stock, valued at approximately $5,390,096. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP John Adam Zangerle sold 3,650 shares of Steris stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total value of $321,200.00. The disclosure for this sale can be found here. Company insiders own 2.55% of the company’s stock.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.